Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: An analysis of integrated data

Anesthesia and Analgesia

Volumn 108, Issue 1, 2009, Pages 299-307

  Schug, Stephan A ^a,b   Joshi, Girish P ^c   Camu, Frederic ^d   Pan, Sharon ^e   Cheung, Raymond ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; IBUPROFEN PLUS OXYCODONE; KETOROLAC; MORPHINE; PARECOXIB; PLACEBO; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ISOXAZOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART INFARCTION; HIP ARTHROPLASTY; HUMAN; INCIDENCE; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; THROMBOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; META ANALYSIS; MIDDLE AGED; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; INCIDENCE; ISOXAZOLES; MALE; MIDDLE AGED; PAIN, POSTOPERATIVE; POSTOPERATIVE CARE; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; THROMBOEMBOLISM; YOUNG ADULT;

EID: 58749107157     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31818ca3ac     Document Type: Article

References (40)

1. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001;61:1133-41
2. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br J Anaesth 2003;90:166-72
3. Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioidsparing following total hip arthroplasty. Anesthesiology 2003;98:950-6
4. Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 2006;104:518-26
5. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2- specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001;23:1422-8
6. Stoltz RR, Harris SI, Kuss ME, LeComte D, Talwalker S, Dhadda S, Hubbard RC. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002;97:65-71
7. Noveck RJ, Laurent A, Kuss M, Talwalker S, Hubbard RC. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals: two randomised, controlled trials. Clin Drug Investig 2001;21:465-76
8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
9. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
10. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
11. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:677-80
12. Brophy JM, Solomon SD, Wittes J, McMurray J, Psaty BM, Furberg CD. Cardiovascular risk associated with celecoxib. N Engl J Med 2005;352:2648-50
13. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81
14. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1310-6
15. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005;330:1370
16. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005;42:312-24
17. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005;52:1968-78
18. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92
19. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
20. Snabes MC, Jakimiuk AJ, Kotarski J, Katz TK, Brown MT, Verburg KM. Parecoxib sodium administered over several days reduces pain after gynecologic surgery via laparotomy. J Clin Anesth 2007;19:448-55
21. Maxwell M, Nathanson M. Parecoxib-getting to the heart of the matter. Anaesthesia 2006;61:823-5
22. Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am J Orthop 2002;31:336-43
23. Barton SF, Langeland FF, Snabes MC, LeComte D, Kuss ME, Dhadda SS, Hubbard RC. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002;97: 306-14
24. Bikhazi GB, Snabes MC, Bajwa ZH, Davis DJ, LeComte D, Traylor L, Hubbard RC. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. Am J Obstet Gynecol 2004;191:1183-91
25. Malan TP Jr, Gordon S, Hubbard R, Snabes M. The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. Anesth Analg 2005;100:454-60
26. Apfelbaum JL, Gan TJ, Zhao S, Hanna DB, Chen C. Reliability and validity of the perioperative opioid-related symptom distress scale. Anesth Analg 2004;99:699-709
27. Gan TJ, Joshi GP, Zhao SZ, Hanna DB, Cheung RY, Chen C. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol Scand 2004;48:1194-207
28. Gan TJ, Joshi GP, Viscusi E, Cheung RY, Dodge W, Fort JG, Chen C. Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 2004;98:1665-73
29. Joshi GP, Viscusi ER, Gan TJ, Minkowitz H, Cippolle M, Schuller R, Cheung RY, Fort JG. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 2004;98:336-42
30. Zhao SZ, Chung F, Hanna DB, Raymundo AL, Cheung RY, Chen C. Dose-response relationship between opioid use and adverse effects after ambulatory surgery. J Pain Symptom Manage 2004;28:35-46
31. Desjardins PJ, Shu VS, Recker DP, Verburg KM, Woolf CJ. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002;97:565-73
32. Reynolds LW, Hoo RK, Brill RJ, North J, Recker DP, Verburg KM. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 2003;25:133-41
33. Camu F, Beecher T, Recker DP, Verburg KM. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002;9:43-51
34. Ekman EF, Gimbel JS, Williams HT, Shapiro DY, Verburg KM. Analgesic efficacy of valdecoxib 40 mg qd in managing acute pain following anterior cruciate ligament reconstruction. Anesthesiology 2004;101:A35
35. Pollak R, Raymond GA, Jay RM, Hillstrom HJ, Mahan KT, Riff D, Jacobs EL, Brown MT, Verburg KM. Analgesic efficacy of valdecoxib for acute postoperative pain after bunionectomy. J Am Podiatr Med Assoc 2006;96:393-407
36. Torres LM, Cabrera J, Martinez J, Calderon E, Fernandez S, Chaves J. The specific COX-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery [in Spanish]. Rev Esp Anestesiol Reanim 2004;51:576-82
37. Pfizer Inc. Summary of study results for valdecoxib clinical study VALA-0513-145. Clinical Study Results org. Available at: http://www. clinicalstudyresults.org/documents/companystudy- 2013-0.pdf. Accessed February 6, 2007
38. Becker RC COX-2 inhibitors. Tex Heart Inst J 2005;32:380-3
39. Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol 2006;48:817-23
40. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003;10:142-9